Abstract
Antibody (Ab) mediated neutralization is a crucial means of host resistance to many pathogens and will most likely be required in the development of a vaccine to protect against HIV-1. Here we examine mechanistic aspects of HIV-1 neutralization with attention to recent studies on the stoichiometric, kinetic and thermodynamic parameters involved. Neutralization of HIV-1, as with any microbe, minimally requires an initial molecular encounter with Ab. Ab occupancy of functional heterotrimers of the envelope glycoproteins, gp120 and gp41 (Env), indeed appears to be the dominant mechanism of neutralization for HIV-1. However, the Ab-binding site, the parameters mentioned above, as well as the stages and duration of vulnerability to Ab recognition, prior to and leading up to viral entry, each have a distinct impact on the mechanism of neutralization for any given Ab specificity. With HIV-1, the problems of mutational variation and neutralization resistance, coupled with the lability and conformational heterogeneity in Env, have stimulated the search for rational approaches to Env immunogen design that are unprecedented in vaccinology.
Keywords: Neutralization mechanism, antibodies, vaccine development, virus fusion
Current HIV Research
Title: HIV-1 Neutralization: Mechanisms and Relevance to Vaccine Design
Volume: 5 Issue: 6
Author(s): Michael B. Zwick and Dennis R. Burton
Affiliation:
Keywords: Neutralization mechanism, antibodies, vaccine development, virus fusion
Abstract: Antibody (Ab) mediated neutralization is a crucial means of host resistance to many pathogens and will most likely be required in the development of a vaccine to protect against HIV-1. Here we examine mechanistic aspects of HIV-1 neutralization with attention to recent studies on the stoichiometric, kinetic and thermodynamic parameters involved. Neutralization of HIV-1, as with any microbe, minimally requires an initial molecular encounter with Ab. Ab occupancy of functional heterotrimers of the envelope glycoproteins, gp120 and gp41 (Env), indeed appears to be the dominant mechanism of neutralization for HIV-1. However, the Ab-binding site, the parameters mentioned above, as well as the stages and duration of vulnerability to Ab recognition, prior to and leading up to viral entry, each have a distinct impact on the mechanism of neutralization for any given Ab specificity. With HIV-1, the problems of mutational variation and neutralization resistance, coupled with the lability and conformational heterogeneity in Env, have stimulated the search for rational approaches to Env immunogen design that are unprecedented in vaccinology.
Export Options
About this article
Cite this article as:
Zwick B. Michael and Burton R. Dennis, HIV-1 Neutralization: Mechanisms and Relevance to Vaccine Design, Current HIV Research 2007; 5 (6) . https://dx.doi.org/10.2174/157016207782418443
DOI https://dx.doi.org/10.2174/157016207782418443 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 TAR RNA: The Target of Molecular Interactions Between the Virus and its Host
Current HIV Research Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses The Role of Cytokines in T Help Responses to Viruses
Current Immunology Reviews (Discontinued) Current Screens Based on the AlphaScreen™ Technology for Deciphering Cell Signalling Pathways
Current Genomics Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets
Current Drug Targets Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets The Nef-Infectivity Enigma: Mechanisms of Enhanced Lentiviral Infection
Current HIV Research Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Molecules of Infectious Agents as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Drosophila Models of Proteinopathies: the Little Fly that Could
Current Pharmaceutical Design